The Mergers and Acquisitions (M&A) landscape for HealthTech and MedTech is poised for a significant strategic acceleration in 2026, transitioning from cautious, volume-driven dealmaking witnessed in previous years to high-value, transformative transactions. This resurgence is supported by stabilising credit markets, renewed corporate confidence, and a critical, anticipated pivot in US. antitrust enforcement policy, which is expected to facilitate large, strategic combinat

The Initial Public Offering (IPO) landscape for the HealthTech and MedTech sectors is projected to undergo a significant recovery in 2026. Following a period of volatility and retrenchment between 2022 and 2024, the confluence of stabilising macroeconomic conditions, investor appetite for disruptive technology and a substantial backlog of highly mature companies suggests that 2026 will be the most active year for public offerings since the market peaks of 2021.

The relationship between medical technology (MedTech) and defence technology has historically been characterised by an ad hoc, one-directional flow of innovation, often described as a "spin-out" effect where military research unexpectedly finds civilian applications. However, a contemporary analysis reveals a more complex, mutually beneficial, and increasingly institutionalized symbiosis. This interdependence is no longer a matter of serendipitous discovery but a deliberate,